Exosomes in primary Sjögren’s disease: diagnostic and therapeutic perspectives from emerging evidence

This correspondence comments on the recent review “Exosomes as immunomodulators in autoimmune inflammation: implications for primary Sjögren’s disease,” emphasizing the dual role of exosomes in primary Sjögren’s disease (pSD). On one side, lymphocyte-derived vesicles contribute to epithelial dysfunction through pathogenic microRNA transfer; on the other, mesenchymal stromal cell-derived exosomes show promising immunomodulatory and regenerative properties. Salivary and tear-derived exosomes emerge as attractive diagnostic tools, although their clinical adoption remains hindered by methodological variability. The discussion extends to systemic involvement, including pulmonary hypertension and cardiovascular risk, highlighting exosomes as potential predictive biomarkers. Overall, the letter underscores the translational opportunities of exosome research in pSD while calling for advances in standardization, targeted delivery, and large-scale production to facilitate clinical integration.